# Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

> **NCT00048633** · PHASE2 · COMPLETED · sponsor: **QLT Inc.** · enrollment: 30 (—)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT00048633
- **Lead sponsor:** QLT Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 30 (—)
- **Last updated:** 2012-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048633, "Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00048633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*